Join us on March 7 for our Educated Patient Summit on Breast Cancer taking place in Miami, FL! 

To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Kristie L. Kahl
In this episode of the “CURE Talks Cancer” podcast, we spoke with Bishoy Tadros, who went on to break barriers after he was diagnosed with acute lymphoblastic leukemia at the age of 3 and immigrated to the United States from Egypt to receive treatment.
Beth Fand Incollingo
The novel drug pairing of Venclexta and Gazyva, used for a fixed 12 months, is cost-effective compared with regimens that must be taken until disease progresses, a study finds.
Katie Kosko
Research findings show that rare mutations from donor stem cells can be passed onto patients who receive them, potentially causing health concerns.
Katie Kosko
With many targeted treatment options for patients with CLL to use upfront, the question arises as to which one is best for the individual.
Dr. Matthew Davids
Researchers are exploring ways to limit the duration of treatment in chronic lymphocytic leukemia in order to reduce costs.
Kristie L. Kahl
Those with follicular lymphoma and chronic lymphocytic leukemia who were treated with Zydelig in the clinical setting experienced less favorable outcomes, compared with those treated in a clinical trial.
Jessica Skarzynski
As 2019 comes to a close, take a read through CURE®’s top stories of the year.
Naval Daver, MD
New findings show that a wider study is needed for MDM2 inhibitors in treating patients with AML.
Rachelle Berfond
When one woman experienced symptoms of chronic lymphocytic leukemia, people blamed her nerves and told her to rest. Instead, she listened to her body.
Tom Castles
Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

Sign In

Not a member? Sign up now!
Continue without login